Arena Pharmaceuticals submits lorcaserin NDA to the FDA Arena Pharmaceuticals.

Arena Pharmaceuticals submits lorcaserin NDA to the FDA Arena Pharmaceuticals, Inc. announced today that it provides submitted a New Drug Program to the US Food and Drug Administration for lorcaserin, Arena’s internally found out and developed drug candidate for weight reduction, including weight loss and maintenance of pounds loss treatment . The submission is based on an extensive data package from lorcaserin’s clinical development program which includes 18 clinical trials totaling 8,576 patients. Related StoriesStudy reveals potential restrictions of app-based method of excess weight lossPoverty and parenting design predict childhood obesityNegative body image significantly increases weight problems risk among adolescentsWilliam R.

Those on the waiting around list face higher prices of homelessness, hospitalization and incarceration, according to county estimates in recent years . Related antiviral treatment decreases disability risk StoriesEarly, hospitalization time in old peopleResearchers identify potential brain-centered biomarker for depressive symptomsScreening for asymptomatic atrial fibrillation could reduce threat of stroke, premature deathHealth Plan Solutions : Treating Mental Health Woes Could Save Billions National leaders will end up being watching an ambitious experiment beginning at 11 sites across Colorado that aims to revolutionize and integrate long-separated primary care and mental wellness.